Regulatory & Legal Notice This product: Is not a medicinal product under the Human Medicines Regulations 2012 Is not authorised or approved by the MHRA Is not intended for human or veterinary use Is not for clinical, diagnostic, or therapeutic application By purchasing this product, the buyer represents and warrants that it will be used solely for lawful laboratory research purposes and in full compliance with all applicable regulatory and institutional requirements
Users who have achieved significant results may choose to continue at a maintenance dose, take a break and reassess, or adjust their protocol in consultation with a healthcare provider
In SLC25A45 negative mice there is an observable increase in glucose oxidation with a concomitant decrease in mitochondrial fatty acid -oxidation
The persistence of acute energy-expenditure and fat-oxidation responses in beta-3-receptor knockout mice indicates that at least some short-term effects occurred without functional beta-3 receptors in that model
Adding too much water dilutes the solution, potentially requiring larger injection volumes that increase discomfort
GPR75 is coupled to a G q -type G-protein and thus, its activation results in increased IP 3 and DAG production